JP2011529691A5 - - Google Patents

Info

Publication number

JP2011529691A5

JP2011529691A5 JP2011521359A JP2011521359A JP2011529691A5 JP 2011529691 A5 JP2011529691 A5 JP 2011529691A5 JP 2011521359 A JP2011521359 A JP 2011521359A JP 2011521359 A JP2011521359 A JP 2011521359A JP 2011529691 A5 JP2011529691 A5 JP 2011529691A5

Authority

JP

Japan

Prior art keywords

mutation

dna

gene

tumor

template

Prior art date

2009-07-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108020004414 DNA Proteins 0.000 claims description 61
• 239000012634 fragment Substances 0.000 claims description 34
• 238000000034 method Methods 0.000 claims description 33
• 239000000523 sample Substances 0.000 claims description 32
• 206010028980 Neoplasm Diseases 0.000 claims description 29
• 230000035772 mutation Effects 0.000 claims description 28
• 239000011324 bead Substances 0.000 claims description 27
• 108090000623 proteins and genes Proteins 0.000 claims description 14
• 238000012360 testing method Methods 0.000 claims description 11
• 230000003321 amplification Effects 0.000 claims description 10
• 239000000839 emulsion Substances 0.000 claims description 10
• 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
• 238000002271 resection Methods 0.000 claims description 10
• 239000000203 mixture Substances 0.000 claims description 9
• 108091093088 Amplicon Proteins 0.000 claims description 8
• 238000009396 hybridization Methods 0.000 claims description 7
• 108700028369 Alleles Proteins 0.000 claims description 6
• OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 claims description 6
• 238000000684 flow cytometry Methods 0.000 claims description 5
• 238000012163 sequencing technique Methods 0.000 claims description 5
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
• 108091034117 Oligonucleotide Proteins 0.000 claims description 4
• 239000012736 aqueous medium Substances 0.000 claims description 4
• 230000000295 complement effect Effects 0.000 claims description 4
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
• 108010090804 Streptavidin Proteins 0.000 claims description 3
• 238000004458 analytical method Methods 0.000 claims description 3
• 238000001816 cooling Methods 0.000 claims description 3
• 239000007762 w/o emulsion Substances 0.000 claims description 3
• 239000012491 analyte Substances 0.000 claims description 2
• 239000008346 aqueous phase Substances 0.000 claims description 2
• 230000001351 cycling effect Effects 0.000 claims description 2
• 238000000295 emission spectrum Methods 0.000 claims description 2
• 239000003995 emulsifying agent Substances 0.000 claims description 2
• 239000012071 phase Substances 0.000 claims description 2
• 239000004094 surface-active agent Substances 0.000 claims description 2
• 238000009098 adjuvant therapy Methods 0.000 claims 5
• 201000011510 cancer Diseases 0.000 claims 4
• 108020004711 Nucleic Acid Probes Proteins 0.000 claims 3
• 239000002853 nucleic acid probe Substances 0.000 claims 3
• 239000008280 blood Substances 0.000 claims 2
• 210000004369 blood Anatomy 0.000 claims 2
• 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 1
• 102100030708 GTPase KRas Human genes 0.000 claims 1
• 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 1
• 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 1
• 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 1
• 108700020796 Oncogene Proteins 0.000 claims 1
• 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 1
• 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 1
• 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 1
• 238000009534 blood test Methods 0.000 claims 1
• 238000012544 monitoring process Methods 0.000 claims 1
• 239000002773 nucleotide Substances 0.000 claims 1
• 125000003729 nucleotide group Chemical group 0.000 claims 1
• 238000002563 stool test Methods 0.000 claims 1
• 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 22
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 22
• 238000001356 surgical procedure Methods 0.000 description 12
• 230000002550 fecal effect Effects 0.000 description 9
• 238000002512 chemotherapy Methods 0.000 description 7
• 201000010099 disease Diseases 0.000 description 6
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
• 230000002980 postoperative effect Effects 0.000 description 6
• 238000003384 imaging method Methods 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 206010009944 Colon cancer Diseases 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 230000003902 lesion Effects 0.000 description 4
• 238000003753 real-time PCR Methods 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 238000012752 Hepatectomy Methods 0.000 description 3
• 238000001325 log-rank test Methods 0.000 description 3
• 230000000306 recurrent effect Effects 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 238000011521 systemic chemotherapy Methods 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 2
• 230000003187 abdominal effect Effects 0.000 description 2
• 238000012321 colectomy Methods 0.000 description 2
• 201000010897 colon adenocarcinoma Diseases 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 102200006532 rs112445441 Human genes 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 210000001599 sigmoid colon Anatomy 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 1
• 230000009946 DNA mutation Effects 0.000 description 1
• 206010061819 Disease recurrence Diseases 0.000 description 1
• 238000001347 McNemar's test Methods 0.000 description 1
• 206010027457 Metastases to liver Diseases 0.000 description 1
• 206010027458 Metastases to lung Diseases 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 210000005162 left hepatic lobe Anatomy 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000011325 microbead Substances 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 210000005163 right hepatic lobe Anatomy 0.000 description 1
• 238000007480 sanger sequencing Methods 0.000 description 1
• 238000013538 segmental resection Methods 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1